Research labs, production areas and administrative offices share the 15,000 square meters of the two floor facility.
CIM conducts clinical trials in diagnostic imaging and cancer therapy of varying origin, as well as other immune system diseases, in highly specialized hospitals.
These vaccine has been associated with statistically significant extension of survival of lung cancer patients with excellent safety profile and continues to be investigated in confirmatory clinical trials.
[1]: 139 Since 1992 CIMAB S.A. has been working on the commercialization of biopharmaceutical products for the Cuban market and abroad, especially monoclonal antibodies and other recombinant proteins for the diagnosis and treatment of cancer and other diseases related to the immune system.
It was announced in July 2008 that CIM had also received approval from the Cuban regulatory authorities for a lung cancer vaccine, targeting EGFR.